Ultragenyx EMA Validates MAA for MPS IIIA Gene Therapy

Ultragenyx announced that the EMA has validated its Marketing Authorisation Application for rebisufligene etisparvovec (UX111) for the treatment of MPS IIIA, allowing for a formal review process. This validation is a regulatory step and does not constitute approval.